Tasonermin is cytotoxic or cytostatic in vitro for a variety of tumour cell lines of different histogenesis. Tasonermin affects the morphology and reduces proliferation of endothelial cells. Also, it has profound effects on cellular components of the immune system.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L03AX11 | Tasonermin | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| BEROMUN Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Tasonermin is an active ingredient of these brands:
Austria (AT)Croatia (HR)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Lithuania (LT)Poland (PL)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
